Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us


Asia Preimplantation Genetic Diagnosis Market Boosted by Increasing Prevalence of Infertility

Article Description

Preimplantation genetic diagnosis (PGD) is the in vitro inspection of an embryo to detect genetic abnormalities. Preimplantation genetic diagnosis is done in cases where there exists a considerably high risk of passing on a serious condition or disorder from the parents to their offspring. Thus, preimplantation genetic diagnosis is emerging as a practical alternative to prenatal diagnosis and termination of pregnancy. The growing incidence of infertility is driving the global preimplantation genetic diagnosis market. Preimplantation genetic diagnosis helps in the detection of sex-related disorders and chromosomal abnormalities in the embryo. PGD applications are growing for screening embryos for susceptibility to cancer, diagnosing onset diseases, Human leukocyte antigen (HLA) matching in existing children for bone marrow or cord blood transplant, and gender selection. Growing awareness about IVF is also boosting the market. 

Browse Full Global Preimplantation Genetic Diagnosis Market Report with TOC :

Rising Number of People Suffering from Genetic Disorders Boosts Preimplantation Genetic Diagnosis Market

The growing desire to ensure that an expected child is healthy is driving the preimplantation genetic diagnosis market. The number of people suffering from genetic disorders is increasing at a fast pace and thus, preimplantation genetic diagnosis is increasingly being utilized due to its high accuracy in detecting genetic abnormalities. The prevalence of hereditary diabetes, breast cancer, asthma, and congenital heart diseases is rising across the globe, resulting in an increased awareness about the importance of diagnosing these diseases, which is boosting the preimplantation genetic diagnosis market.  PGD is beneficial for couples going through IVF for infertility due to advanced maternal age.

On the other hand, the high cost of preimplantation genetic diagnosis may hamper the market. Since PGD is a relatively new medical technology, some technicians may need more practice to perform the testing and biopsy correctly. Another factor that could restrain the market is the inconsistency of the PGD process in case of two or more different patterns of chromosomes in a cell.

Aneuploidy Screening Dominates Preimplantation Genetic Diagnosis Market

The preimplantation genetic diagnosis market in Asia is segmented on the basis of end user, test type, and geography. On the basis of type, the market is segmented into aneuploidy screening, gender selection, chromosomal aberrations, HLA typing, X-linked diseases, and single gene disorder. Out of these, the aneuploidy screening segment accounted for the largest share, 35%, in the preimplantation genetic diagnosis market in Asia. Aneuploidy screening detects an embryo with chromosomal abnormalities.

Geographically, the preimplantation genetic diagnosis market in Asia is segmented into Southern Asia, South Eastern Asia, Eastern Asia, Western Asia, and Central Asia. In 2014, Eastern Asia accounted for the largest share in the PGD market in Asia. Eastern Asia comprises South Korea, China, Japan, and Rest of Eastern Asia. The PGD market in the region is expected to expand due to rising medical tourism, presence of untapped opportunities, and rising awareness among people regarding health care.

Major players operating in the preimplantation genetic diagnosis market are: Reproductive Genetics Innovations LLC (U.S.), Quest Diagnostics Incorporated (U.S.), Genea Limited (Australia), Laboratory Corporation of America Holdings (U.S.), Natera, Inc. (U.S.), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Reprogenetics (U.S.), and Genesis Genetics (U.S.).